|
|
Topic |
Authors / presenters |
Event name |
Event date |
| 1. |
|
Combination co-stimulatory modulation: Moving from mouse to man |
Curran MA, Callahan, M., Allison JP, and Wolchok J |
MDACC Melaoma Seminar Series |
March, 2013 |
| 2. |
|
Systemic 4-1BB activation induces a novel T-cell phenotype driven by high expression of Eomesodermin |
Curran MA, Kim MJ, Reiner, SL, Montalvo, WM, Al-Shamkhani A, Sun, J, Allison JP |
MDACC Center for Cancer Immunology Research Retreat |
December, 2012 |
| 3. |
|
Combination hypoxia-specific chemotherapy and immunotherapy cures established murine prostate cancer |
Curran MA, Subhudhi, S., Allison JP |
Cancer Research Institute Annual Meeting |
October, 2012 |
| 4. |
|
Systemic 4-1BB activation induces a novel T-cell phenotype driven by high expression of Eomesodermin |
Curran MA, Kim MJ, Reiner, SL, Montalvo, WM, Al-Shamkhani A, Sun, J, Allison JP |
American Association of Immunologists Annual Meeting |
May, 2012 |
| 5. |
|
4-1BB agonist antibody treatment induces production of IL-15 and IL-27 by antigen presenting cells driving the formation of a novel Eomes-dependent lineage of cytotoxic CD4+ and CD8+ T-cells |
Curran MA, Kim MJ, Reiner, SL, Montalvo, WM, Al-Shamkhani A, Sun, J, Allison JP. |
Society for Immunotherapy of Cancer Annual Meeting |
October, 2011 |
| 6. |
|
4-1BB agonist antibody treatment induces production of IL-15 and IL-27 by antigen presenting cells driving the formation of a novel Eomes-dependent lineage of cytotoxic CD4+ and CD8+ T-cells |
Curran MA, Kim MJ, Reiner, SL, Montalvo, WM, Al-Shamkhani A, Sun, J, Allison JP |
Cancer Research Institute Annual Meeting |
October, 2011 |
| 7. |
|
4-1BB agonist antibody treatment causes intra-tumoral accumulation of KLRG1+ CD8+ and CD4+ T-cells with a novel highly cytotoxic phenotype driven by the master-regulator Eomesodermin |
Curran MA, Kim MJ, Montalvo, WM, Al-Shamkhani A, Allison JP |
American Association of Immunologists Annual Meeting |
May, 2011 |
| 8. |
|
4-1BB activation induces the master-regulator Eomes and a broad-spectrum TH1 phenotype which synergizes with CTLA-4 blockade to reject B16 melanoma |
Curran MA, Kim MJ, Al-Shamkhani A, Allison JP |
Cancer Research Institute Annual Meeting |
October, 2010 |
| 9. |
|
4-1BB activation induces the master-regulator Eomes and broad-spectrum TH1 phenotype which synergizes with CTLA-4 blockade to reject B16 melanoma |
Curran MA, Kim MJ, Al-Shamkhani A, Allison JP |
International Society for Biological Therapy of Cancer Annual Meeting |
October, 2010 |
| 10. |
|
PD-1 and CTLA-4 combination blockade expands infiltrating T-cells and reduces regulatory T and myeloid cells within B16 melanoma tumors |
Curran MA, Montalvo W, Yagita H, Allison JP |
Keystone Symposia |
February, 2010 |
| 11. |
|
Cellular tumor vaccines expressing Flt3-ligand (FL3vax) synergize with a broad spectrum of immuno-adjuvant antibodies to drive the rejection of established tumors |
Curran MA, Allison JP |
Mobilizing Cellular Immunity for Cancer Therapy |
January, 2009 |
| 12. |
|
Cellular tumor vaccines expressing Flt3-ligand synergize with CTLA-4 blockade to reject established tumors |
Curran MA, Allison JP |
AACR Annual Meeting |
April, 2008 |
| 13. |
|
Adjuvants and alternatives for autologous tumor vaccination |
Curran MA, Allison JP |
American Association of Immunologists Annual Meeting |
May, 2006 |
How We Rank
